IKT Insider Trading (Inhibikase Therapeutics)
Insider Ownership Percentage: 55.80%
Insider Buying (Last 12 Months): $46,470.33
Insider Selling (Last 12 Months): $0.00
Inhibikase Therapeutics Share Price & Price History
Current Price: $0.67
Price Change: ▼ Price Decrease of -0.04 (-5.63%)
As of 05/18/2022 05:00 PM ET
The Last Great Value Stock
From Oxford Club | Ad
Last year it was more profitable than Disney, Square or even Tesla.
But it's just under $2 per share.
This company's unusual business model has created a rare situation where it is both cheap and highly profitable, but it may not be $2 for long.
Check out the free presentation by clicking here.
>>>
Inhibikase Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/17/2021 | Milton H. Werner | CEO | Buy | 23,589 | $1.97 | $46,470.33 | |  |
The Last Great Value Stock
From Oxford Club | Ad
Last year it was more profitable than Disney, Square or even Tesla.
But it's just under $2 per share.
This company's unusual business model has created a rare situation where it is both cheap and highly profitable, but it may not be $2 for long.
Check out the free presentation by clicking here.
>>>
Inhibikase Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/13/2022 | Vanguard Group Inc. | 530,098 | $0.79M | 0.0% | +10.7% | 2.101% |  |
| 5/6/2022 | Retirement Planning Co of New England Inc. | 116,402 | $0.17M | 0.1% | -21.0% | 0.461% | |
| 5/5/2022 | Lynwood Capital Management Inc. | 120,000 | $0.18M | 0.2% | -52.9% | 0.476% | |
| 5/4/2022 | Hamilton Lane Advisors LLC | 165,635 | $0.25M | 0.1% | N/A | 0.657% | |
| 5/3/2022 | Redmond Asset Management LLC | 122,682 | $0.18M | 0.1% | N/A | 0.486% | |
| 2/14/2022 | Murchinson Ltd. | 220,947 | $0.33M | 0.0% | -31.2% | 0.878% | |
| 2/14/2022 | State Street Corp | 56,900 | $84K | 0.0% | N/A | 0.226% | |
| 2/11/2022 | Geode Capital Management LLC | 79,128 | $0.12M | 0.0% | +206.3% | 0.314% | |
| 2/11/2022 | Renaissance Technologies LLC | 201,200 | $0.30M | 0.0% | N/A | 0.799% | |
| 2/8/2022 | Retirement Planning Co of New England Inc. | 147,331 | $0.22M | 0.1% | N/A | 0.586% | |
| 2/8/2022 | Northern Trust Corp | 28,872 | $42K | 0.0% | +83.7% | 0.115% | |
| 2/3/2022 | ACT Capital Management LLC | 1,076,500 | $1.58M | 1.1% | +6.6% | 4.279% | |
| 11/18/2021 | Bank of New York Mellon Corp | 39,580 | $75K | 0.0% | N/A | 0.157% | |
| 11/16/2021 | ACT Capital L.L.C. | 1,010,000 | $1.92M | 1.0% | +15.4% | 4.019% | |
| 11/16/2021 | Warberg Asset Management LLC | 26,000 | $49K | 0.0% | -71.1% | 0.103% | |
| 11/16/2021 | Millennium Management LLC | 101,278 | $0.19M | 0.0% | N/A | 0.403% | |
| 11/12/2021 | Geode Capital Management LLC | 25,833 | $49K | 0.0% | N/A | 0.103% | |
| 11/10/2021 | Goldman Sachs Group Inc. | 27,895 | $53K | 0.0% | N/A | 0.111% | |
| 11/9/2021 | BlackRock Inc. | 50,741 | $96K | 0.0% | +273.9% | 0.202% | |
| 8/17/2021 | Zeke Capital Advisors LLC | 93,800 | $0.26M | 0.0% | +398.9% | 0.926% | |
| 8/16/2021 | Antara Capital LP | 250,000 | $0.70M | 0.0% | N/A | 2.467% | |
| 8/16/2021 | Warberg Asset Management LLC | 90,000 | $0.25M | 0.0% | N/A | 0.888% | |
| 8/16/2021 | Sabby Management LLC | 421,200 | $1.18M | 0.2% | N/A | 4.157% | |
| 8/13/2021 | Altium Capital Management LP | 109,749 | $0.31M | 0.1% | N/A | 1.083% | |
| 8/13/2021 | Murchinson Ltd. | 320,947 | $0.90M | 0.3% | N/A | 3.167% | |
| 8/13/2021 | Vanguard Group Inc. | 470,615 | $1.32M | 0.0% | N/A | 4.644% | |
| 8/13/2021 | FMR LLC | 433,300 | $1.21M | 0.0% | +333.3% | 4.276% | |
| 8/12/2021 | Kepos Capital LP | 700,000 | $1.96M | 0.1% | N/A | 6.908% | |
| 5/21/2021 | Citadel Advisors LLC | 17,857 | $0.11M | 0.0% | N/A | 0.178% | |
| 5/18/2021 | Millennium Management LLC | 11,224 | $67K | 0.0% | N/A | 0.112% | |
| 5/18/2021 | Citadel Advisors LLC | 17,857 | $0.11M | 0.0% | N/A | 0.178% | |
| 5/17/2021 | HRT Financial LP | 11,614 | $69K | 0.0% | N/A | 0.115% | |
Data available starting January 2016
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Read More on Inhibikase Therapeutics
Volume
119,004 shs
Average Volume
117,600 shs
Market Capitalization
$16.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.24
Who are the company insiders with the largest holdings of Inhibikase Therapeutics?
Who are the major institutional investors of Inhibikase Therapeutics?
Which major investors are selling Inhibikase Therapeutics stock?
In the last quarter, IKT stock was sold by these institutional investors:
- Lynwood Capital Management Inc.
- Retirement Planning Co of New England Inc.
Which major investors are buying Inhibikase Therapeutics stock?
In the last quarter, IKT stock was bought by institutional investors including:
- Hamilton Lane Advisors LLC
- Redmond Asset Management LLC
- Vanguard Group Inc.
